ACTR-73. A PHASE II STUDY OF TUMOR TREATING FIELDS IN COMBINATION WITH BEVACIZUMAB AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED, UNRESECTABLE GLIOBLASTOMA

BACKGROUND: Patients with newly diagnosed, unresectable glioblastoma multiforme (GBM) will usually receive concurrent temozolomide (TMZ) and radiation therapy. Some patients will also receive bevacizumab (BEV) if clinically indicated. Tumor treating fields (TTFields) have also been shown to be safe...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Sumrall, Ashley, Haggstrom, Daniel, Burri, Stuart, Symanowski, James
Format: Artigo
Language:Inglês
Published: Oxford University Press 2017
Subjects:
Abstracts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692684/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.060
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items